ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO0671

NF-kB Inhibitor Enhances Galactose Deficiency of IgA1 and Modulates Activation of Multiple Transcription Factors in Immortalized B Cells from Patients with IgAN and Healthy Control Participants

Session Information

Category: Glomerular Diseases

  • 1401 Glomerular Diseases: Mechanisms, including Podocyte Biology

Authors

  • Person, Taylor, The University of Alabama at Birmingham Department of Medicine, Birmingham, Alabama, United States
  • Reily, Colin, The University of Alabama at Birmingham Department of Medicine, Birmingham, Alabama, United States
  • Novak, Jan, The University of Alabama at Birmingham Department of Microbiology, Birmingham, Alabama, United States
  • Rizk, Dana V., The University of Alabama at Birmingham Department of Medicine, Birmingham, Alabama, United States
Background

EBV-immortalized B cells from IgA nephropathy (IgAN) patients and healthy controls (HC) have been used to study mechanisms of production of galactose-deficient IgA1 (Gd-IgA1). GWAS identified IgAN-risk alleles in REL and RELA loci, suggesting NF-kB involvement. However, the role of NF-kB-signaling pathway in IgA1 O-glycosylation is not well understood. We used a small-molecule inhibitor of NF-kB (TPCA-1) to assess involvement of NF-kB pathway in Gd-IgA1 production in IgA1-secreting cells.

Methods

Immortalized B cells derived from peripheral blood of IgAN patients and HC were incubated with TPCA-1 (4 μM) for 1 h or 48 h prior to staining and flow cytometry. Cell-culture media were used for IgA1 and Gd-IgA1 analyses. B cells were stained with antibodies for conventional cell-surface markers, and with HPA lectin to detect cell-surface GalNAc-containing glycoconjugates; intracellular staining detected activated transcription factors. Gene expression was determined by qPCR.

Results

TPCA-1 decreased production of total IgA (p<0.01) whereas the proportion of Gd-IgA1 increased (p<0.01) in all cells. TPCA-1 decreased C1GALT1 expression (p=0.01), but had no effect on COSMC. TPCA-1 decreased phospho-IKKa/b (p=0.04), pSTAT3 (p<0.01), and pERK1/2 (p<0.01). HPA-positive cells had greater CD138 and IgA staining and high SSA-A (side-scatter area) values (p<0.01), indicating a plasma-cell-like phenotype. These cells had a higher baseline activation of all three tested phospho-proteins (p<0.01) compared to the cells with low SSA-A values. Furthermore, 48-h incubation with TPCA-1 increased the proportion of the cells with plasma-cell-like phenotype (p<0.01).

Conclusion

Immortalized B cells exhibited substantial heterogeneity in both baseline transcription-factor activation and distribution of B-cell subtypes. NF-kB inhibitor decreased production of IgA1, increased proportion of Gd-IgA1, and increased proportion of cells with plasma-cell-like phenotype. These IgA1 and cell-surface glycophenotypes were likely due to a reduced expression of C1GALT1. Future studies will determine the critical abnormal signaling interactions controlling IgA1 glycosylation.

Funding

  • NIDDK Support

Digital Object Identifier (DOI)